id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FTC-2022-0062-0004,FTC,FTC-2022-0062,HISA Anti-Doping and Medication Control Rule; Correction,Notice,,2022-11-04T04:00:00Z,2022,11,,,2022-11-04T14:22:50Z,2022-24016,0,0,09000064854883e1
FTC-2022-0062-0003,FTC,FTC-2022-0062,Exhibit B - Supporting Documents on which HISA Relied.pdf1,Supporting & Related Material,,2022-11-01T04:00:00Z,2022,11,,,2022-11-01T14:25:11Z,,0,0,0900006485478045
FTC-2022-0062-0002,FTC,FTC-2022-0062,Exhibit A - Stakeholder Comments on HISA ADMC Proposed Rules (002),Supporting & Related Material,,2022-11-01T04:00:00Z,2022,11,,,2022-11-01T14:24:49Z,,0,0,090000648541adb7
FTC-2022-0062-0001,FTC,FTC-2022-0062,HISA Anti-Doping and Medication Control Rule,Notice,,2022-10-28T04:00:00Z,2022,10,2022-10-28T04:00:00Z,2022-11-15T04:59:59Z,2023-01-21T02:00:59Z,2022-22970,0,0,090000648546a16e